Article
JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.
PLoS pathogens - 1 Apr 2014
Sundqvist Emilie, Buck Dorothea, Warnke Clemens, Albrecht Eva, Gieger Christian, Khademi Mohsen, Lima Bomfim Izaura, Fogdell-Hahn Anna, Link Jenny, Alfredsson Lars, Søndergaard Helle Bach, Hillert Jan, Oturai Annette B, Hemmer Bernhard, Hemme Bernhard, Kockum Ingrid, Olsson Tomas
Abstract excerpt
JC polyomavirus (JCV) carriers with a compromised immune system, such as in HIV, or subjects on immune-modulating therapies, such as anti VLA-4 therapy may develop progressive multifocal leukoencephalopathy (PML) which is a lytic infection of oligodendrocytes in the brain. Serum antibodies to JCV mark infection occur only in 50-60% of infected individuals, and high JCV-antibody titers seem to increase the risk of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
